Effects of Novel Hydrazone Derivatives on Endometrial Cancer Cells
Author Information
Author(s): Bulbul Muhammet Volkan, Mermer Arif, Kolbasi Bircan, Kocabas Fatih, Kalender Semiha Mervenur, Kirectepe Aydin Kiymet Asli, Demircan Turan, Keskin İlknur
Primary Institution: Department of Histology and Embryology, School of Medicine, Agri Ibrahim Cecen University, Turkey
Hypothesis
The study evaluates the anticancer activity of two novel hydrazone derivatives against type 1 endometrial cancer cells.
Conclusion
MVB1 and MVB2, especially MVB1, are promising candidates for further development as potential therapeutics for endometrial cancer by targeting the PI3K/AKT/mTOR pathway.
Supporting Evidence
- MVB1 and MVB2 showed promising anticancer activity with IC50 values of 8.3 ± 0.5 µM and 9.0 ± 1.2 µM in 2D cultures.
- MVB1 exhibited the highest mean binding score (−10.5 kcal/mol) among PI3K, AKT1, and mTOR proteins.
- In vitro studies confirmed that MVB1 effectively suppressed PI3K protein expression in both 2D and 3D cultures.
Takeaway
Researchers created two new compounds to fight a type of cancer in the uterus, and one of them showed great promise in stopping cancer cells from growing.
Methodology
The anticancer activity of MVB1 and MVB2 was evaluated using MTT assays in both 2D and 3D cultured Ishikawa cells, along with molecular docking studies and in vitro western blot analyses.
Statistical Information
P-Value
p ≤ 0.0001
Statistical Significance
p ≤ 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website